The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats

Brain Research

Volumn 729, Issue 1, 1996, Pages 124-126

  Chapman, Mary Ann ^a,b   See, Ronald E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GABA; Glycine; Microdialysis; Neurotensin; Rat; SR 48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID; GLYCINE; NEUROTENSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030570827     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00407-6     Document Type: Article

References (18)

1. [1] Bourdelais, A. and Kalivas, P.W., High sensitivity HPLC assay for GABA in brain dialysis studies, J. Neurosci. Methods, 39 (1991) 115-121.
2. [2] Brun, P., Steinberg, R., LeFur, G. and Soubrie, P., Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens, J. Neurochem., 64 (1995) 2073-2079.
3. [3] Chapman, M.A., See, R.E. and Bissette G., Neurotensin increases extracellular striatal dopamine levels in vivo, Neuropeptides, 22 (1992) 175-183.
4. [4] Ervin, G.N. and Nemeroff, C.B., Interactions of neurotensin with dopamine-containing neurons in the central nervous system, Prog. Neuro-Psychopharm. Biol. Psychiatry, 12 (1988) S53-S69.
5. [5] Fuxe, K., von Euler, G., Agnati, L.F., Merlo Pich, E., O'Connor, W.T., Tanganelli, S., Li, X.M., Tinner, B., Cintra, A., Carani, C. and Benfenati, F., Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. In P. Kitabgi and C.B. Nemeroff (Eds.), The Neurobiology of Neurotensin, Annals of the New York Academy of Sciences, Vol. 668, New York Academy of Science, New York, 1992, pp. 186-204.
6. [6] Gully, D., Canton, M., Boigegrain, R., Jeanjean, F., Molimard, J.-C., Poncelet, M., Guedet, C., Heaulme, M., Leyris, R., Brouard, A., Pelaprat, D., Labbe-Jullie, C., Mazella, J., Soubrie, P., Maffrand, J.-P., Rostene, W., Kitabgi, P. and LeFur, G., Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor, Proc. Natl. Acad. Sci. USA, 90 (1993) 65-69.
7. [7] Hosli, E., Stauffer, S. and Hosli, L., Autoradiographic and electrophysiological evidence for the existence of neurotensin receptors on cultured astrocytes, Neuroscience, 66 (1995) 627-633.
8. [8] Jolicoeur, F.B., Rivest, R., St.-Pierre, S. and Drumheller, A., Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats, Brain Res., 538 (1991) 187-192.
9. [9] Masuo, Y., Montagne, M-N., Pelaprat, D., Scherman, D. and Rostene, W., Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density, Brain Res., 520 (1990) 6-13.
10. [10] Murai, S., Saito, H., Abe, E., Masuda, Y. and Itoh, T., A rapid assay for neurotransmitter amino acids, aspartate, glutamate, glycine, taurine and gamma-aminobutyric acid in the brain by high-performance liquid chromatography with electrochemical detection. J. Neural Transm. [Gen. Section], 87 (1992) 145-153.
11. [11] Nemeroff, C.B., Neurotensin: Perchance an endogenous neuroleptic? Biol. Psychiatry, 15 (1980) 283-302.
12. [12] O'Connor, W.T., Tanganelli, S., Ungerstedt, U. and Fuxe, K., The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: an in vivo microdialysis study, Brain Res., 573 (1992) 209-216.
13. [13] Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, Baltimore, 1986.
14. [14] Robinson, T.E. and Whishaw, I.Q., Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats, Brain Res., 450, (1988) 209-224.
15. [15] Steinberg, R., Brun, P., Fournier, M., Souilhac, J., Rodier, D., Mons, G., Terranova, J.P., LeFur, G. and Soubrie, P., SR 48692, a nonpeptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission, Neuroscience, 59 (1994) 921-929.
16. [16] Tanganelli, S., von Euler, G., Fuxe, K., Agnati, L.F. and Ungerstedt, U., Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum, Brain Res., 502 (1989) 319-324.
17. [17] Westerink, B.H.C. and de Vries, J.B., On the origin of extracellular GABA collected by brain microdialysis and assayed by a simplified on-line method, Naunyn-Schmiedeberg's Arch. Pharmacol., 339 (1989) 603-607.
18. [18] Yadid, G., Pacak, K., Golomb, E., Harvey-White, J.D., Lieberman, D.M., Kopin, I.J. and Goldstein, D.S., Glycine stimulates striatal dopamine release in conscious rats, Br. J. Pharmacol., 110 (1993) 50-53.